Events Calendar
May 29-June 2
American Society of Clinical Oncology
Virtual
Poster Presentations:
Ph 2 trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNβ and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma
Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors
Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC) for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy
December 3-5, 2019
Oncolytic Virotherapy Summit
Boston, MA
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Pharmico-Dynamic Non-Invasive Monitoring Techniques”
October 28-31, 2019
World Vaccine Congress Europe 2019
Barcelona, Spain
Shruthi Naik, Ph.D., Vyriad Vice President of Comparative Oncology
Presentation: “Unlocking the Potential of Oncolytic Viruses to Target Cancer Cells”
October 9-12, 2019
International Oncolytic Virus 12th Annual Conference
Rochester, MN
Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer
Opening Remarks
Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Inflaming tumors with systemic VSV therapy”
August 8, 2019
Cambridge Healthtech Institutes (CHI) 2nd Annual Immuno-Oncology Investing & Partnering Forum
Boston, MA
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Novel Therapeutics and Diagnostics for Cancer Immunotherapy”
August 6-7, 2019
Cambridge Health Institute’s (CHI) 4th Annual Oncolytic Virus Immunotherapy Summit
Boston, MA
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Systemic OV Therapy Using Voyager-V1”
July 21-23, 2019
The 25th Annual Meeting of Japan Society of Gene and Cell Therapy and The International Gene & Cell Therapy Symposium
Tokyo, Japan
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: "Intravenous Virotherapy: Inflaming Tumors via the Blood Stream"
April 10-11, 2019
Cambridge Healthtech Institute’s Inaugural Oncolytic Viral Therapy Conference: Engineering, Translational and Clinical Strategies
Boston, MA
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Antibody Targeted Viruses: The Next Generation of Oncolytics”
March 18-22, 2019
Immuno-Oncology Summit Europe
London, UK
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Vyriad’s Voyager-V1 Program: Pharmacological Enhancement of a Systemically Active, Single Cycle Oncolytic Virus”
March 11-13, 2019
Cambridge Healthtech Institute’s 4th Annual Cancer Immunotherapy: Executive Summit
San Francisco, CA
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Voyager-V1: Systemic, Single-cycle, Trackable Oncolytic Virotherapy”
February 11-12, 2019
Bio CEO and Investor Conference
New York, NY
Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer
Presentation: “Oncolytic Viruses for IV Cancer Therapy"
January 7-10, 2019
37th Annual JP Morgan Healthcare Conference
San Francisco, CA
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, and Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, attended the 37th Annual JP Morgan Healthcare Conference in San Francisco.
December 4-6, 2018
4th Oncolytic Virotherapy Summit
Boston, MA
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Vyriad’s Voyager-V1 Program: Pharmacological Enhancement of a Systemically Active, Single Cycle Oncolytic Virus.”
Dr. Russell will also co-chair a panel session entitled: Comparing and Contrasting Virus Types.
November 27-29, 2018
30th Annual Piper Jaffray Healthcare Conference
New York, NY
Stephen J. Russell, M.D., Ph.D., Vyriad President and CEO, attended the 30th Annual Piper Jaffray Healthcare Conference in New York.
August 27-28, 2018
Cambridge Healthtech Institute’s 3rd Annual Oncolytic Virus Immunotherapy: Commercializing the Exciting Potential of Oncolytic Virotherapy
Boston, MA
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Progress with Oncolytic Vesicular Stomatitis Viruses”
June 26-28, 2018
Armed Oncolytic Immunotherapies Summit
Frankfurt, Germany
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Systemic Cancer Therapy Using Oncolytic VSVs: The Voyager Platform”
Dr. Russell will participate in a panel discussion, "Explore Novel Approaches to Identify the Most Rational Combinations“
June 1-5, 2018
American Society of Clinical Oncology (ASCO) Annual Meeting
Chicago, Illinois
Alice Bexon, M.D., Vyriad Chief Medical Officer will attend the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
May 16-19, 2018
18th Annual American Society of Cell & Gene Therapy (ASGCT) meeting
Chicago, IL
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, has been elected Vice-President of ASGCT. ASGCT has elected four new members to the Board of Directors, including Dr. Stephen J. Russell as new incoming vice president. Dr. Russell will serve a yearlong term as vice president before serving as ASGCT's president-elect and, finally, president through the 2021 annual meeting. Dr. Russell will be Co-Chairing: Clinical Trials Spotlight I at the annual meeting. Kah-Whye Peng, Ph.D., Vyriad Chief Technology Officer, has been invited to present: Use of Novel Transgenic NIS Reporter Rats for Longitudinal Tracking of Fibrogenesis by High-Resolution Imaging and Use of Novel Transgenic NIS Reporter Rats for Longitudinal Tracking of Fibrogenesis by High-Resolution Imaging
April 9-12, 2018
International Oncolytic Virus Conference
Oxford, UK
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, has been invited to Chair, Innate and collateral adaptive tumor immunity. Dr. Russell will also participate in Steve Russell (Once should be enough!) vs. Alan Melcher (Repeat dosing is crucial!) Kah-Whye Peng, Ph.D., Vyriad Chief Technology Officer, has been invited to Chair, Translation, imaging and clinical breakthroughs. Dr. Peng will be presenting: Oncolytic virus encoding IFNbeta: optimizing therapeutic index.
January 8-11, 2018
36th Annual JP Morgan Healthcare Conference
San Francisco, CA
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, and Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, attended the 36th Annual JP Morgan Healthcare Conference in San Francisco.
December 5-7, 2017
Oncolytic Virotherapy Summit
Miami, Florida
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, was invited as a panel member for: How Can We Improve the Efficacy of Oncolytic Virotherapies? Dr. Russell also provided a presentation entitled “VSV-IFNb-NIS and MV-NIS: A Tale of Two Paradigms” and managed a workshop entitled “Optimizing Oncolytic Viruses: Identifying the Right Viral Platform”
November 28-29, 2017
28th Annual Piper Jaffray Healthcare Conference
New York, New York
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, presented “Oncolytic Virotherapy: The Next Major Breakthrough in Cancer Treatment” at the 28th Annual Piper Jaffray Healthcare Conference
November 8-12, 2017
The 32nd Annual Society for Immunotherapy of Cancer (SITC) meeting
National Harbor, Maryland
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, attended the annual SITC meeting
November 4, 2017
Dr. Boenjamin Setiawan Distinguished Lectureship for 2017
Jakarta, Indonesia
Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Invited to present “Oncolytic Viruses: An Emerging Cornerstone for Immuno-oncology” at the Dr. Boenjamin Setiawan Distinguished Lecture Series
February 23-25, 2017
ASCO-SITC Clinical Immuno-Oncology Symposium
Orlando, Florida
Stephen J Russell from Vyriad was invited to present on "Viral Therapy" at the ASCO-SITC conference on exploiting viruses for cancer therapy in combination with immune modulators.
October 1-4, 2016
The 10th International Meeting on Replicating Oncolytic Virus Therapeutics
Vancouver, Canada
Kah-Whye Peng, PhD, CTO of Vyriad gave a Plenary presentation entitled “Vesicular stomatitis virus (VSV) as an oncolytic agent”. Stephen J. Russell, MD, PhD, CEO & President of Vyriad gave a Plenary presentation entitled “Measles as a versatile oncolytic agent”.
June 18, 2016
35th Annual Meeting of the American Society of Virology
Blacksburg, VA
Keynote Lecture: “Oncolytic Viruses: Past, Present, and Future” Stephen J. Russell, MD, PhD, CEO & President, Vyriad.